Evoke Pharma (EVOK) Stock Price, News & Analysis

Company Overview

Evoke Pharma, Inc. is a clinical-stage specialty pharmaceutical company focused on developing novel therapies for gastrointestinal (GI) motility disorders. The company’s lead product candidate, relamorelin, is a selective ghrelin receptor agonist designed to restore gastric motility and accelerate gastric emptying in conditions such as diabetic gastroparesis. Relamorelin has been granted orphan drug designation by the U.S. Food and Drug Administration and has demonstrated proof-of-concept activity in multiple clinical trials, positioning it as a promising treatment for patients with impaired GI function.

In addition to relamorelin, Evoke Pharma is advancing earlier-stage programs targeting metabolic and GI conditions, leveraging its expertise in peptide chemistry and receptor pharmacology. The company’s research efforts aim to extend the therapeutic potential of ghrelin receptor modulation into related indications, including postoperative ileus and chronic constipation. Evoke collaborates with academic and industry partners to optimize its pipeline and expand clinical development into new patient populations.

Founded in 2006 and headquartered in San Diego, California, Evoke Pharma completed its initial public offering on the Nasdaq under the ticker EVOK. The company serves patients across the United States and is exploring opportunities to establish international partnerships for broader market access. Evoke’s leadership team combines decades of experience in gastroenterology drug development, regulatory affairs and commercial strategy to advance its mission of improving quality of life for individuals with debilitating GI disorders.

Key Stats

• Today's Range: $10.98 to $11.00
• 50-Day Range: $10.67 to $11.00
• 52-Week Range: $2.28 to $11.00
• Volume: 47,100 shs
• Average Volume: 983,927 shs
• Market Capitalization: $18.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:EVOK
• CIK: 1403708
• Web: www.evokepharma.com
• Phone: (858) 345-1494
• Fax: N/A
• Employees: 4
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): ($2.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.35 million
• Net Margins: -36.23%
• Pretax Margin: -36.23%
• Return on Equity: -101.40%
• Return on Assets: -31.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.27
• Quick Ratio: 1.22

Sales & Book Value

• Annual Sales: $10.25 million
• Price / Sales: 1.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.74 per share
• Price / Book: 2.32

Miscellaneous

• Outstanding Shares: 1,720,000
• Free Float: 1,683,000
• Market Cap: $18.92 million
• Optionable: Not Optionable
• Beta: -0.15